Dofetilide Patent Expiration

Dofetilide is Used for treating cardiac arrhythmia. It was first introduced by Pfizer Pharmaceuticals Production Corp Ltd in its drug Tikosyn on Oct 1, 1999. 14 different companies have introduced drugs containing Dofetilide.


Dofetilide Patents

Given below is the list of patents protecting Dofetilide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tikosyn US6124363 Dofetilide polymorphs Oct 09, 2018

(Expired)

Pfizer
Tikosyn US4959366 Anti-arrhythmic agents Sep 25, 2012

(Expired)

Pfizer



Dofetilide's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Dofetilide Generic API Manufacturers

Several generic applications have been filed for Dofetilide. The first generic version for Dofetilide was by Dr Reddys Laboratories Sa and was approved on Jun 6, 2016. And the latest generic version is by Teva Pharmaceuticals Usa Inc and was approved on Apr 15, 2022.

Given below is the list of companies who have filed for Dofetilide generic, along with the locations of their manufacturing plants worldwide.